{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:42:33Z","timestamp":1792600953961,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["FIKP IGSZF\/123338-2\/2021-ITMFIKP IGSZF\/123338-2\/2021-ITM"],"award-info":[{"award-number":["FIKP IGSZF\/123338-2\/2021-ITMFIKP IGSZF\/123338-2\/2021-ITM"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-026-02584-2","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:38:07Z","timestamp":1792553887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Memantine in the treatment of dementia: a nationwide real-world analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3070-5285","authenticated-orcid":false,"given":"Petra Marica","family":"Halmos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-4104","authenticated-orcid":false,"given":"Bal\u00e1zs","family":"Dobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Vinnai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Ajtay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8374-0500","authenticated-orcid":false,"given":"D\u00e1niel","family":"Bereczki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8603-8848","authenticated-orcid":false,"given":"Tibor","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"11","key":"2584_CR1","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nrneurol.2014.181","volume":"10","author":"PS Sachdev","year":"2014","unstructured":"Sachdev PS, Blacker D, Blazer DG, et al. Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol. 2014;10(11):634\u201342. https:\/\/doi.org\/10.1038\/nrneurol.2014.181.","journal-title":"Nat Rev Neurol"},{"key":"2584_CR2","unstructured":"World Health Organization. Global action plan on the public health response to dementia 2017\u20132025. Geneva: World Health Organization; 2017. https:\/\/www.who.int\/publications\/i\/item\/9789241513487."},{"key":"2584_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.4470","author":"JP Ney","year":"2021","unstructured":"Ney JP, Steinmetz JD, Anderson-Benge E, et al. US burden of disorders affecting the nervous system: from the global burden of disease 2021 study. JAMA Neurol. 2021. https:\/\/doi.org\/10.1001\/jamaneurol.2025.4470.","journal-title":"JAMA Neurol"},{"issue":"5","key":"2584_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.18553\/jmcp.2008.14.5.451","volume":"14","author":"L Mucha","year":"2008","unstructured":"Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer\u2019s disease. J Manag Care Pharm. Jun2008;14(5):451\u201361. https:\/\/doi.org\/10.18553\/jmcp.2008.14.5.451.","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"2584_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003154.pub6","volume":"3","author":"R McShane","year":"2019","unstructured":"McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3(3):CD003154. https:\/\/doi.org\/10.1002\/14651858.CD003154.pub6.","journal-title":"Cochrane Database Syst Rev"},{"key":"2584_CR6","doi-asserted-by":"publisher","unstructured":"Zolnowski-Kolp V, Oquendo B, Havreng-Thery C, Lafuente-Lafuente C, Belmin J. Effect of long-term treatment with memantine on mortality in patients with major cognitive disorders: a systematic review and meta-analysis. Alzheimers Dement (N Y). 2025;11(2):e70071. https:\/\/doi.org\/10.1002\/trc2.70071.","DOI":"10.1002\/trc2.70071"},{"key":"2584_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/alz.073714","author":"WS Weidner","year":"2022","unstructured":"Weidner WS. World Alzheimer report 2022 \u2010 how strong are global health systems: lessons learned and case studies from across the globe. Alzheimers Dement. 2022. https:\/\/doi.org\/10.1002\/alz.073714.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2584_CR8","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/ene.13645","volume":"25","author":"F Oberfrank","year":"2018","unstructured":"Oberfrank F, Ajtay A, Bereczki D. Demand for neurological services in Central Eastern Europe: a 10-year national survey in Hungary. Eur J Neurol. 2018;25(7):984\u201390. https:\/\/doi.org\/10.1111\/ene.13645.","journal-title":"Eur J Neurol"},{"issue":"1","key":"2584_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11357-021-00470-7","volume":"44","author":"N Balazs","year":"2022","unstructured":"Balazs N, Bereczki D, Ajtay A, Oberfrank F, Kovacs T. Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary. Geroscience. 2022;44(1):253\u201363. https:\/\/doi.org\/10.1007\/s11357-021-00470-7.","journal-title":"Geroscience"},{"key":"2584_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/217047","volume":"2015","author":"WY Lam","year":"2015","unstructured":"Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047. https:\/\/doi.org\/10.1155\/2015\/217047.","journal-title":"Biomed Res Int"},{"issue":"4","key":"2584_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/jac5.1771","volume":"6","author":"KK Shah","year":"2023","unstructured":"Shah KK, Touchette DR, Marrs JC. Research and scholarly methods: measuring medication adherence. J Am Coll Clin Pharm. 2023;6(4):416\u201326. https:\/\/doi.org\/10.1002\/jac5.1771.","journal-title":"J Am Coll Clin Pharm"},{"key":"2584_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2147\/CLEP.S153496","volume":"10","author":"I Arnet","year":"2018","unstructured":"Arnet I, Greenland M, Knuiman MW, et al. Operationalization and validation of a novel method to calculate adherence to polypharmacy with refill data from the Australian pharmaceutical benefits scheme (PBS) database. Clin Epidemiol. 2018;10:1181\u201394. https:\/\/doi.org\/10.2147\/CLEP.S153496.","journal-title":"Clin Epidemiol"},{"key":"2584_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/PPA.S492461","volume":"19","author":"W Jannah","year":"2025","unstructured":"Jannah W, Khoiry QA, Alfian SD, Abdulah R. Suitability of measures of pharmacy-based medication adherence for routine clinical use among patients with chronic diseases: a systematic review. Patient Prefer Adherence. 2025;19:265\u201378. https:\/\/doi.org\/10.2147\/PPA.S492461.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"2584_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/17582024.2025.2590936","volume":"16","author":"L Lv","year":"2026","unstructured":"Lv L, Aly A, McKay C, et al. Real-world analysis of medication adherence and cost of care for comorbid conditions in patients with early Alzheimer\u2019s disease in the U.S. Neurodegener Dis Manag. 2026;16(1):53\u201361. https:\/\/doi.org\/10.1080\/17582024.2025.2590936.","journal-title":"Neurodegener Dis Manag"},{"key":"2584_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf151","author":"M Sistanizad","year":"2025","unstructured":"Sistanizad M, Peterson GM, Ling T, Salahudeen MS, Akondi VM, Bezabhe WM. Persistence with anti-dementia medications: a systematic review and meta-analysis. Age Ageing. 2025. https:\/\/doi.org\/10.1093\/ageing\/afaf151.","journal-title":"Age Ageing"},{"issue":"3","key":"2584_CR16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3233\/JAD-220200","volume":"90","author":"H Fukuda","year":"2022","unstructured":"Fukuda H, Maeda M, Murata F, Murata Y. Anti-dementia drug persistence following donepezil initiation among Alzheimer\u2019s disease patients in Japan: LIFE study. J Alzheimers Dis. 2022;90(3):1177\u201386. https:\/\/doi.org\/10.3233\/JAD-220200.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"2584_CR17","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s10072-022-06586-8","volume":"44","author":"I Ippoliti","year":"2023","unstructured":"Ippoliti I, Ancidoni A, Da Cas R, Pierantozzi A, Vanacore N, Trotta F. Anti-dementia drugs: a descriptive study of the prescription pattern in Italy. Neurol Sci. 2023;44(5):1587\u201395. https:\/\/doi.org\/10.1007\/s10072-022-06586-8.","journal-title":"Neurol Sci"},{"issue":"9","key":"2584_CR18","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/gps.4892","volume":"33","author":"Y Okumura","year":"2018","unstructured":"Okumura Y, Sakata N. Antidementia drug use in Japan: bridging the research-to-practice gap. Int J Geriatr Psychiatry. 2018;33(9):1286\u20137. https:\/\/doi.org\/10.1002\/gps.4892.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"2584_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12014","volume":"6","author":"R Wurm","year":"2020","unstructured":"Wurm R, Stamm T, Reichardt B, et al. Prescription patterns of antidementives in a high income country: a pharmacoepidemiologic study. Alzheimers Dement (N Y). 2020;6(1):e12014. https:\/\/doi.org\/10.1002\/trc2.12014.","journal-title":"Alzheimers Dement (N Y)"},{"key":"2584_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1425442","volume":"15","author":"E Gutierrez-Abejon","year":"2024","unstructured":"Gutierrez-Abejon E, Pedrosa-Naudin MA, Fernandez-Lazaro D, Diaz Planelles I, Alvarez FJ. Non-adherence to antidementia medications and associated factors: a study of Spanish population-based registry data. Front Pharmacol. 2024;15:1425442. https:\/\/doi.org\/10.3389\/fphar.2024.1425442.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2584_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01271-0","volume":"15","author":"J Olazaran","year":"2023","unstructured":"Olazaran J, Carnero-Pardo C, Fortea J, et al. Prevalence of treated patients with Alzheimer\u2019s disease: current trends and COVID-19 impact. Alzheimers Res Ther. 2023;15(1):130. https:\/\/doi.org\/10.1186\/s13195-023-01271-0.","journal-title":"Alzheimers Res Ther"},{"key":"2584_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afae106","author":"C Reyes","year":"2024","unstructured":"Reyes C, Newby D, Raventos B, et al. Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study. Age Ageing. 2024. https:\/\/doi.org\/10.1093\/ageing\/afae106.","journal-title":"Age Ageing"},{"issue":"1","key":"2584_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12206","volume":"7","author":"C Ju","year":"2021","unstructured":"Ju C, Lau WCY, Hayes JF, et al. Impact of the COVID-19 pandemic on use of anti-dementia medications in 34 European and North American countries. Alzheimers Dement Transl Res Clin Interv. 2021;7(1):e12206. https:\/\/doi.org\/10.1002\/trc2.12206.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"1","key":"2584_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03447-5","volume":"23","author":"JR DiBello","year":"2023","unstructured":"DiBello JR, Lu Y, Swartz J, et al. Patterns of use of symptomatic treatments for Alzheimer\u2019s disease dementia (AD). BMC Neurol. 2023;23(1):400. https:\/\/doi.org\/10.1186\/s12883-023-03447-5.","journal-title":"BMC Neurol"},{"issue":"3","key":"2584_CR25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/13872877251319468","volume":"104","author":"C Becker","year":"2025","unstructured":"Becker C, Herschung L, Gomm W, Haenisch B. Dementia diagnosis and prescription of antidementia drugs: an analysis of German claims data (2006-2016). J Alzheimers Dis. 2025;104(3):698\u2013708. https:\/\/doi.org\/10.1177\/13872877251319468.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2584_CR26","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3233\/JAD-190288","volume":"71","author":"M Linna","year":"2019","unstructured":"Linna M, Vuoti S, Silander K, et al. Impact of anti-dementia medication on the risk of death and causes of death in Alzheimer\u2019s Disease. J Alzheimers Dis. 2019;71(4):1297\u2013308. https:\/\/doi.org\/10.3233\/JAD-190288.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"2584_CR27","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"2584_CR28","unstructured":"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers (NICE guideline NG97). Internet. https:\/\/www.nice.org.uk\/guidance\/ng97. Accessed 11 Mar 2026."},{"issue":"6","key":"2584_CR29","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503\u201327. https:\/\/doi.org\/10.1093\/brain\/awz099.","journal-title":"Brain"},{"issue":"6","key":"2584_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755\u201366. https:\/\/doi.org\/10.1007\/s00401-014-1349-0.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"2584_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40266-017-0481-7","volume":"34","author":"M Francois","year":"2017","unstructured":"Francois M, Sicsic J, Elbaz A, Pelletier Fleury N. Trends in drug prescription rates for dementia: an observational population-based study in France, 2006-2014. Drugs Aging. 2017;34(9):711\u201321. https:\/\/doi.org\/10.1007\/s40266-017-0481-7.","journal-title":"Drugs Aging"},{"key":"2584_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6930","volume":"367","author":"S Walsh","year":"2019","unstructured":"Walsh S, King E, Brayne C. France removes state funding for dementia drugs. BMJ. 2019;367:l6930. https:\/\/doi.org\/10.1136\/bmj.l6930.","journal-title":"BMJ"},{"issue":"4","key":"2584_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/pds.4921","volume":"29","author":"M Francois","year":"2020","unstructured":"Francois M, Sicsic J, Pelletier-Fleury N. Determinants of antidementia drug prescription in patients older than 65: a latent class analysis. Pharmacoepidemiol Drug Saf. 2020;29(4):444\u201352. https:\/\/doi.org\/10.1002\/pds.4921.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2584_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0379-6","volume":"10","author":"VM Walker","year":"2018","unstructured":"Walker VM, Davies NM, Kehoe PG, Martin RM. What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink. Alzheimers Res Ther. 2018;10(1):51. https:\/\/doi.org\/10.1186\/s13195-018-0379-6.","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"2584_CR35","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamaneurol.2025.2236","volume":"82","author":"JB Lusk","year":"2025","unstructured":"Lusk JB, Ford CB, Soneji S, et al. Sex differences in mortality and health care utilization after dementia diagnosis. JAMA Neurol. 2025;82(10):1048\u201356. https:\/\/doi.org\/10.1001\/jamaneurol.2025.2236.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2584_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70177","volume":"17","author":"R Amland","year":"2025","unstructured":"Amland R, Selbaek G, Braekhus A, Rhodius-Meester HFM, Strand BH. Sex differences in life expectancy in dementia, mild cognitive impairment (MCI), and subjective cognitive decline (SCD). Alzheimers Dement (Amst). 2025;17(3):e70177. https:\/\/doi.org\/10.1002\/dad2.70177.","journal-title":"Alzheimers Dement (Amst)"},{"key":"2584_CR37","doi-asserted-by":"publisher","first-page":"233372142094592","DOI":"10.1177\/2333721420945922","volume":"6","author":"L White","year":"2020","unstructured":"White L, Fishman P, Basu A, Crane PK, Larson EB, Coe NB. Dementia is associated with earlier mortality for men and women in the United States. Gerontol Geriatr Med Jan-Dec. 2020;6:2333721420945922. https:\/\/doi.org\/10.1177\/2333721420945922.","journal-title":"Gerontol Geriatr Med Jan-Dec"},{"issue":"12","key":"2584_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004124","volume":"19","author":"S Chen","year":"2022","unstructured":"Chen S, Price AC, Cardinal RN, et al. Association between antidementia medication use and mortality in people diagnosed with dementia with Lewy bodies in the UK: a retrospective cohort study. PLoS Med. 2022;19(12):e1004124. https:\/\/doi.org\/10.1371\/journal.pmed.1004124.","journal-title":"PLoS Med"},{"key":"2584_CR39","unstructured":"National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for thetreatment of Alzheimer\u2019s disease. Technology appraisal guidance [TA217]. London: NICE; 2011 (last updated 20 June 2018). https:\/\/www.nice.org.uk\/guidance\/ta217."},{"issue":"1","key":"2584_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12877-018-0857-5","volume":"18","author":"L Blanco-Silvente","year":"2018","unstructured":"Blanco-Silvente L, Capella D, Garre-Olmo J, Vilalta-Franch J, Castells X. Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer\u2019s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients. BMC Geriatr. 2018;18(1):168. https:\/\/doi.org\/10.1186\/s12877-018-0857-5.","journal-title":"BMC Geriatr"},{"issue":"5","key":"2584_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012419.pub2","volume":"5","author":"AJ Cross","year":"2020","unstructured":"Cross AJ, Elliott RA, Petrie K, Kuruvilla L, George J. Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. Cochrane Database Syst Rev. 2020;5(5):CD012419. https:\/\/doi.org\/10.1002\/14651858.CD012419.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2584_CR42","doi-asserted-by":"publisher","first-page":"254248232513729","DOI":"10.1177\/25424823251372924","volume":"9","author":"M Guba-Menzel","year":"2025","unstructured":"Guba-Menzel M, Hussenoeder FS, Kostev K. Persistence with antidementia therapy in Germany: a retrospective cohort study of 567,815 patients. J Alzheimers Dis Rep. 2025;9:25424823251372924. https:\/\/doi.org\/10.1177\/25424823251372924.","journal-title":"J Alzheimers Dis Rep"},{"issue":"1","key":"2584_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.35772\/ghm.2023.01047","volume":"6","author":"M Ishihara","year":"2024","unstructured":"Ishihara M, Matsunaga S, Islam R, Shibata O, Chung UI. A policy overview of Japan\u2019s progress on dementia care in a super-aged society and future challenges. Glob Health Med. 2024;6(1):13\u20138. https:\/\/doi.org\/10.35772\/ghm.2023.01047.","journal-title":"Glob Health Med"},{"issue":"2","key":"2584_CR44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14283\/jpad.2024.32","volume":"11","author":"K Malzbender","year":"2024","unstructured":"Malzbender K, Barbarino P, Barkman Ferrell P, et al. Validation, deployment, and real-world implementation of a modular toolbox for Alzheimer\u2019s disease detection and dementia risk reduction: the AD-RIDDLE project. J Prev Alzheimers Dis. 2024;11(2):329\u201338. https:\/\/doi.org\/10.14283\/jpad.2024.32.","journal-title":"J Prev Alzheimers Dis"},{"key":"2584_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100576","volume":"26","author":"GB Frisoni","year":"2023","unstructured":"Frisoni GB, Altomare D, Ribaldi F, et al. Dementia prevention in memory clinics: recommendations from the European task force for brain health services. Lancet Reg Health Eur. Mar2023;26:100576. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100576.","journal-title":"Lancet Reg Health Eur"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02584-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-026-02584-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02584-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:02:07Z","timestamp":1792598527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-026-02584-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":45,"alternative-id":["2584"],"URL":"https:\/\/doi.org\/10.1007\/s11357-026-02584-2","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}